Progenics Pharmaceuticals Inc

Progenics Pharmaceuticals — Merger or Acquisition (October 2019)

16 slides from Progenics Pharmaceuticals's merger presentation, Oct 2, 2019

  1. Slide 1: Combination Creates a Leading Precision Diagnostics and Therapeutics Company

    Exhibit 99.2 \s) Lantheus Progeni , Holdings « enics Combination Creates a Leading Precision Diagnostics and Therapeutics Company October 2, 2019

  2. Slide 2: Safe Harbor Statements: Important Information For Investors And Stockholders

    Safe Harbor Statements Important Information For Investors And Stockholders This document does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval in any jurisdiction in which such offer, solicitation or sale would be unlawf

  3. Slide 3: Compelling Strategic Rationale

    Compelling Strategic Rationale Robust portfolio and pipeline of precision diagnostic and therapeutic products Leadership with strong commercial, operational and financial expertise; aligned with stockholder interests Sustainable and diversified revenue growth with focus on commercial execution excel

  4. Slide 4: Transaction Summary

    Transaction Summary Lantheus Holdings to acquire 100% of Progenics’ common shares structured in a tax-free all-stock transaction Progenics stockholders to receive 0.2502 Lantheus Holdings shares for each Progenics share Implies 21.5% premium to Progenics’ 30-day volume weighted average closing stock

  5. Slide 5: Lantheus' Three Growth Pillars to Enhance Long-Term Stockholder Value

    Lantheus’ Three Growth Pillars to Enhance Long-Term Stockholder Value Enhance Core Enhance growth trajectory of core microbubble business Grow Externally Pursue selective transactions to support our growth Invest in emerging technologies within our pipeline Invest in Pipeline

  6. Slide 6: Lantheus – Extensive Presence in the Radiopharmaceutical Industry

    Lantheus – Extensive Presence in the Radiopharmaceutical Industry Supply Chain & Logistics Number of Radiopharmaceutical Suppliers Worldwide Highly Regulated — Local, State, Federal, & International Agencies Relationships with Radiopharmacies, Hospitals and Payers Product Development & Commercializa

  7. Slide 7: Compelling Strategic Fit in Radiopharmaceuticals

    First and Only FDA Approved Product for Ultra-Orphan Indications in Pheo and Para Additional Life Cycle Opportunties to Treat Other Neuroendocrine Tumor Types Late Stage PSMA Diagnostic Candidate and Promising Therapeutic Product Candidates Integrated PSMA Product Platform, Including AI, Addressing

  8. Slide 8: Well-balanced Portfolio of Marketed Assets Spanning Diagnostics to Therapeutics

    DEFINITY Benefits from unparalleled market and brand position Dedicated salesforce that drives advocacy and awareness Long-standing relationships with sonographers/echocardiologists New formulation has patent protection to 2035 Radiopharmaceuticals Cardiolite recognized as most widely-used diagnosti

  9. Slide 9: Near-Term Value Creation Opportunities From this Transaction

    Near-Term Value Creation Opportunities From this Transaction Ultra-Orphan radiotherapeutic Shown to help address the dual goals of treating advanced pheo / para: tumor reduction and symptom control Focused on delivering targeted solutions to address patients’ needs while creating significant value f

  10. Slide 10: Robust Combined Pipeline with Clear Value Drivers

    Legend: DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 FILING DEFINITY Octafluoropropane - Left Ventricular Ejection Fraction DEFINITY Octafluoropropane - Room Temperature Formulation Flurpiridaz F 18 PET Myocardial Perfusion Imaging LMI 1195 Flubrobenguane - Neuroendocrine Tumors in Pediatric / Adul

  11. Slide 11: Strong Financial Outlook

    Strong Financial Outlook Gross margin improvement potential through enhanced revenue growth and realizable cost savings and efficiencies Additional longer-term opportunities from diversified revenue / product mix Gross Margins Enhanced free cash flow with improved top line growth, operational execut

  12. Slide 12: Combination Highlights

    Robust portfolio and pipeline of precision diagnostic and therapeutic products Leadership with strong commercial, operational and financial expertise; aligned with stockholder interests Sustainable and diversified revenue growth with focus on commercial execution excellence Attractive financial prof

  13. Slide 13: Appendix

    APPENDIX = Laritttelis ] Holdings i Piven emcs

  14. Slide 14: Lantheus Overview

    Lantheus Overview #1 in Ultrasound Contrast Agents Innovating in Microbubble applications Across Microbubble and Radiopharmaceuticals Dynamic Pipeline Manufacturing, Supply Chain and Commercial Expertise Operational Excellence Leader in Radio- pharmaceuticals Pioneer in Radiopharmaceutical Diagnosti

  15. Slide 15: Progenics Overview

    Progenics Overview Company Overview Oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer Promising key pipeline products have potential to fuel long-term growth Therapeutic agents designed to precisely target cancer (1095 and PSMA TTC) PSMA-ta

  16. Slide 16: Safe Harbor Statements: Cautionary Statement Regarding Forward-Looking Statements

    Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties and are made pursuant to the safe harbor provision

Progenics Pharmaceuticals — Merger or Acquisition (October 2019) on 6ix